Does HIV reporting by name deter testing?

被引:29
作者
Hecht, FM
Chesney, MA
Lehman, JS
Osmond, D
Vranizan, K
Colman, S
Keane, D
Reingold, A
Bindman, AB
机构
[1] Univ Calif San Francisco, Posit Hlth Program, HIV Sect, San Francisco, CA 94110 USA
[2] Univ Calif San Francisco, Ctr AIDS Prevent Studies, San Francisco, CA 94110 USA
[3] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94110 USA
[4] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA
[5] Ctr Dis Control & Prevent, Natl Ctr HIV STD & TB Prevent, Div HIV AIDS Prevent Surveillance & Epidemiol, Atlanta, GA USA
[6] San Francisco Gen Hosp, Primary Care Res Ctr, San Francisco, CA 94110 USA
[7] Lewin TAG, San Francisco, CA USA
关键词
disease surveillance; HIV antibody testing; HIV epidemiology; HIV reporting;
D O I
10.1097/00002030-200008180-00016
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: Name-based HIV reporting is controversial in the United States because of concerns that it may deter high-risk persons from being tested. We sought to determine whether persons at risk of HIV infection knew their state's HIV reporting policy and whether they had delayed or avoided testing because of it. Design: A cross-sectional anonymous survey. Methods: We interviewed 2404 participants in one of three high-risk groups: men who have sex with men (MSM), heterosexuals attending a sexually transmitted disease (STD) clinic, and street-recruited injection drug users (IDU). Participants were asked standardized questions about their knowledge of reporting policies and reasons for having delayed or avoided testing. We recruited in eight US states: four with name-based reporting and four without; all offered anonymous testing at certain sites. Results: Fewer than 25% correctly identified their state's HIV reporting policy. Over 50% stated they did not know whether their state used name-based reporting. Of the total, 480 participants (20%) had never been tested. Of these, 17% from states with name-based reporting selected concern about reporting as a reason for not testing compared with 14% from states without name-based reporting (P = 0.5). Comparing previously tested participants from states with name-based reporting to those from states without, concern about HIV reporting was given as a reason for delaying testing by 26% compared with 13% of IDU (P < 0.001), and for 26% compared with 19% of MSM (P = 0.06). Conclusion: Most participants did not know their state's HIV reporting policy. Name-based reporting policies were not associated with avoiding HIV testing because of worry about reporting, although they may have contributed to delays in testing among some IDU. (C) 2000 Lippincott Williams & Wilkins.
引用
收藏
页码:1801 / 1808
页数:8
相关论文
共 15 条
[1]  
[Anonymous], 1999, MMWR Recomm Rep, V48, P1
[2]  
[Anonymous], 1997, MMWR Recomm Rep, V46, P1
[3]  
Bayer Ronald, 1989, PRIVATE ACTS SOCIAL
[4]  
Centers for Disease Control and Prevention, 1998, HIV PARTN COUNS REF
[5]  
Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V46, P1254
[6]   MANDATORY REPORTING OF HUMAN IMMUNODEFICIENCY VIRUS TESTING WOULD DETER BLACKS AND HISPANICS FROM BEING TESTED [J].
FORDYCE, EJ ;
SAMBULA, S ;
STONEBURNER, R .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1989, 262 (03) :349-349
[7]   National HIV case reporting for the United States - A defining moment in the history of the epidemic [J].
Gostin, LO ;
Ward, JW ;
Baker, AC .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (16) :1162-1167
[8]   A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less [J].
Hammer, SM ;
Squires, KE ;
Hughes, MD ;
Grimes, JM ;
Demeter, LM ;
Currier, JS ;
Eron, JJ ;
Feinberg, JE ;
Balfour, HH ;
Dayton, LR ;
Chodakewitz, JA ;
Fischl, MA .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (11) :725-733
[9]   A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter [J].
Hammer, SM ;
Katzenstein, DA ;
Hughes, MD ;
Gundacker, H ;
Schooley, RT ;
Haubrich, RH ;
Henry, WK ;
Lederman, MM ;
Phair, JP ;
Niu, M ;
Hirsch, MS ;
Merigan, TC ;
Blaschke, TF ;
Simpson, D ;
McLaren, C ;
Rooney, J ;
Salgo, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (15) :1081-1090
[10]  
Infuso A, 2000, Euro Surveill, V5, P13